TG-1701, a Selective Bruton Tyrosine Kinase (BTK) Inhibitor, as Monotherapy and in Combination with Ublituximab and Umbralisib (U2) in Patients with Chronic Lymphocytic Leukemia

Drug Category : Array
Conference Category : Array
Lead Author : Cheah C, et al.
Published Date : 19/09/2021
Download Link : https://www.tgtherapeutics.com/wp-content/uploads/2021/09/Cheah-iwCLL-2021-1701-mono-U2-9.19.21.pdf
Download Text : Download
Popup Confirmation? :
site-sidebar-layout : default
ast-site-content-layout : default
site-content-style : default
site-sidebar-style : default
theme-transparent-header-meta : default
stick-header-meta : default
astra-migrate-meta-layouts : set
Scroll to Top